Faeth Therapeutics (FTH) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed MiMedx Group (MDXG) over the past year, gaining 124.6% versus a loss of 32.5%. Over five years, MDXG leads with a -30.9% price change compared with -83.2% for FTH. MiMedx Group is the larger company by market cap ($681.5 million vs $672.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | MDXG |
|---|---|---|
| Share price | $26.03 | $4.67 |
| Market cap | $672.63M | $681.51M |
| 1-day change | +1.64% | +1.08% |
| YTD return | +143.96% | -31.02% |
| 1-year return | +124.59% | -32.51% |
| 5-year return | -83.22% | -30.92% |
| P/E ratio (TTM) | — | 116.75 |
| Forward P/E | — | 23.35 |
| EPS (TTM) | $-60.86 | $0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.14 | $7.97 |
| 52-week low | $7.45 | $3.03 |
| Distance from 52-week high | -38.23% | -41.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +117.71% | +58.46% |
| Average volume | 356.67K | 1.23M |
| Shares outstanding | 25.84M | 145.93M |
| Employees | 29 | 808 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed MDXG by 157.1 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
FTH vs MDXG FAQ
Which is bigger, Faeth Therapeutics or MiMedx Group?
MiMedx Group (MDXG) is larger, with a market capitalization of $681.51M compared with $672.63M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, FTH or MDXG?
FTH returned +124.59% over the past 12 months, compared with -32.51% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and MiMedx Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Faeth Therapeutics and Medical/Dental Instruments for MiMedx Group.